Beyond blood sugar: dapagliflozin’s expanding role in diabetes care
Tracks
1
| Sunday, August 3, 2025 |
| 9:50 AM - 10:30 AM |
| Pyrmont Theatre |
Details
Diabetes management is evolving beyond traditional glycaemic control, including recent expansion of the PBS for earlier treatment. This session uses dapagliflozin as a case study to explore the expanding scope of diabetes therapies, highlighting its emerging roles in cardiovascular and renal protection. Participants will examine the clinical evidence behind these extended benefits, understand the underlying mechanisms, and discuss practical strategies for integrating these advancements into everyday pharmacy practice.
Learning objectives
- Identify the expanding clinical indications and recent PBS changes for diabetes therapies with a focus on dapagliflozin.
- Discuss the clinical evidence supporting dapagliflozin’s benefits in cardiovascular and renal protection.
- Describe the evolving role of pharmacists in optimising patient outcomes with advanced diabetes therapies.
Competency standards (2016): 3.3, 3.5
Speakers
Deborah Hawthorne
Deborah Hawthorne Consultancy
Beyond blood sugar
Biography
Deborah Hawthorne is a consultant pharmacist, recently elected as the chair of Pharmaceutical Society of Australia’s Consultant Pharmacist Community of Special Interest. She brings a wealth of knowledge from a varied career portfolio includes working as a pharmacist in GP clinics, Credentialed Diabetes Educator at Northeast Wangaratta Hospital, Home Medicines Reviews, Residential Medication Management Reviews, Chemical Restraint Consultations, Telehealth Medication Reviews, clinical education and research as an adjunct senior lecturer at the University of Western Australia.
She is also a current Victorian branch committee member of PSA and a board member of the Pharmaceutical Society of Victoria (PSV). She has also been awarded PSA Consultant Pharmacist of the year 2023 and PSA Early Career Pharmacist of the year 2022.
